Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT03421119

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Cinnagen (from the registry)
Registry
  • NCT NCT03421119
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03421119. Randomized; triple masking; primary purpose treatment. Start 2019-06-20 (anticipated); primary completion 2019-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Liraglutide 6 MG/ML Pen Injector
Intervention (Drug)
Metformin
Intervention (Drug)
Sulfonylurea/non-sulfonylurea insulin secretagogues
Lead sponsor
Cinnagen (class: industry)

Record details

Record id
cardio:ct-nct03421119
Content hash
0647b56b64241f653558a314051e21250a0fb80926c9064a2e91dc6c1957d131